267 active trials 153 recruiting 28 Phase 3 177 sponsors 33 changes in 30 days
| Early Phase 1 | 3 | |
| Phase 1 | 54 | |
| Phase 1/2 | 30 | |
| Phase 2 | 70 | |
| Phase 2/3 | 7 | |
| Phase 3 | 21 | |
| Phase 4 | 1 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT05891249 | A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of… | Bristol-Myers Squibb | Active, Not Recruiting | 2025-10-20 |
| Phase 3 | ||||
| NCT04628026 | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients… | University of Ulm | Recruiting | 2026-08-24 |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk… | Takeda | Recruiting | 2026-08-21 |
| NCT06465953 | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With… | Institut de Recherches Internationales Servier | Recruiting | 2026-08-05 |
| NCT07422480 | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low… | Takeda | Recruiting | 2026-07-22 |
| NCT07702578 | A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic… | TScan Therapeutics, Inc. | Recruiting | 2026-07-22 |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other… | Celgene | Recruiting | 2026-07-01 |
| NCT07396480 | Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan… | First Affiliated Hospital of Zhejiang University | Recruiting | 2026-03-17 |
| NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly… | Stichting Hemato-Oncologie voor Volwassenen Nederland | Recruiting | 2025-08-19 |
| NCT04184505 | Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting | 2025-04-29 |
| NCT05153226 | GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG | DKMS gemeinnützige GmbH | Active, Not Recruiting | 2026-08-27 |
| NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine… | Ruijin Hospital | Not Yet Recruiting | 2026-07-29 |
| NCT07722988 | A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating… | Kyntra Bio | Not Yet Recruiting | 2026-07-23 |
| NCT05949684 | ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants… | Bristol-Myers Squibb | Active, Not Recruiting | 2026-06-30 |
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants… | Institut de Recherches Internationales Servier | Active, Not Recruiting | 2026-06-29 |
| NCT07653581 | rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia | Peking Union Medical College Hospital | Not Yet Recruiting | 2026-06-17 |
| NCT04401748 | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change… | AbbVie | Active, Not Recruiting | 2026-05-06 |
| NCT04547049 | A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From… | First Affiliated Hospital of Zhejiang University | Active, Not Recruiting | 2026-04-09 |
| NCT06927232 | AZA+Lus VS AZA Monotherapy in HR-MDS | Peking Union Medical College Hospital | Not Yet Recruiting | 2025-04-15 |
| NCT03223961 | A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS | Groupe Francophone des Myelodysplasies | Active, Not Recruiting | 2025-03-11 |
| NCT05674539 | Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic… | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Enrolling by Invitation | 2025-02-10 |
| NCT03682536 | A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa… | Celgene | Active, Not Recruiting | 2024-11-20 |
| Phase 2/3 | ||||
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With… | M.D. Anderson Cancer Center | Recruiting | 2026-08-11 |
| NCT06895538 | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic… | Peking University First Hospital | Recruiting | 2026-08-05 |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell… | Ruijin Hospital | Recruiting | 2025-05-18 |
M.D. Anderson Cancer Center (7) · Bristol-Myers Squibb (6) · First Affiliated Hospital of Zhejiang University (6) · Ruijin Hospital (6) · Washington University School of Medicine (6) · National Cancer Institute (NCI) (5) · St. Jude Children's Research Hospital (5) · Dana-Farber Cancer Institute (4) · Groupe Francophone des Myelodysplasies (4) · National Heart, Lung, and Blood Institute (NHLBI) (4)